In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival

Journal of Hepatology

Volumn 53, Issue 2, 2010, Pages 313-317

  Rudolph, Gerda ^a   Gotthardt, Daniel ^a   Kloeters Plachky, Petra ^a   Rost, Daniel ^a   Kulaksiz, Hasan ^a   Stiehl, Adolf ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Biliary disease; Cholestasis; Dominant stenosis; Inflammatory bowel disease; Liver disease; Sclerosing cholangitis; Ursodeoxycholic acid

Indexed keywords

ALKALINE PHOSPHATASE; CIPROFLOXACIN; GAMMA GLUTAMYLTRANSFERASE; IOPAMIDOL; MESALAZINE; METHYLPREDNISOLONE; MEZLOCILLIN; NETILMICIN; URSODEOXYCHOLIC ACID;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL CHOLANGITIS; BACTERIAL INFECTION; BALLOON DILATATION; BILE DUCT CARCINOMA; BILE DUCT OBSTRUCTION; CLINICAL TRIAL; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG INTERMITTENT THERAPY; ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPIC SPHINCTEROTOMY; FEMALE; FOLLOW UP; GALLBLADDER CARCINOMA; HUMAN; INCIDENCE; LIVER BIOPSY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; STENT; SURVIVAL; ULCERATIVE COLITIS; BILE DUCT NEOPLASMS; CHOLANGITIS, SCLEROSING; CHOLESTASIS; COLORECTAL NEOPLASMS; COMORBIDITY; COMPLICATION; GALLBLADDER NEOPLASMS; INFLAMMATORY BOWEL DISEASES; KAPLAN MEIER METHOD; LONGITUDINAL STUDY; MIDDLE AGED; MORTALITY; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BILE DUCT NEOPLASMS; CHOLANGITIS, SCLEROSING; CHOLESTASIS; COLORECTAL NEOPLASMS; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; GALLBLADDER NEOPLASMS; HUMANS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; KAPLAN-MEIERS ESTIMATE; LIVER TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL RATE; URSODEOXYCHOLIC ACID; YOUNG ADULT; KAPLAN-MEIER ESTIMATE;

EID: 77955306342     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.02.030     Document Type: Article

References (32)

1. R.W. Chapman, B.A. Arborgh, J.M. Rhodes, J.A. Summerfield, R. Dick, and P.J. Scheuer Primary sclerosing cholangitis - a review of its clinical features, cholangiography and hepatic histology Gut 21 1980 870 877
2. R.H. Wiesner, and N.F. LaRusso Clinicopathologic features of the syndrome of primary sclerosing cholangitis Gastroenterology 79 1980 200 206
3. M.J. Farrant, K.M. Hayllar, M.L. Wilkinson, J. Karani, B.C. Portmann, and D. Westaby Natural history and prognostic variables in primary sclerosing cholangitis Gastroenterology 100 1991 1710 1717
4. Y.-M. Lee, and M.M. Kaplan Primary sclerosing cholangitis N Engl J Med 332 1995 924 933
5. U. Broome, R. Olsson, L. Lööf, G. Bodemar, R. Hultcrantz, and A. Danielsson Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis Gut 38 1996 610 615
6. U. Beuers, U. Spengler, W. Kruis, Ü Aydemir, B. Wiebecke, and W. Heldwein Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo controlled trial Hepatology 16 1992 707 714
7. A. Stiehl, S. Walker, L. Stiehl, G. Rudolph, W.J. Hofmann, and L. Theilmann Effects of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3 year pilot study with a placebo-controlled study period J Hepatol 20 1994 57 64
8. K.D. Lindor, and the Mayo PSC/UDCA study group Ursodiol for the treatment of primary sclerosing cholangitis N Engl J Med 336 1997 691 695
9. S.A. Mitchell, D.S. Bansi, N. Hunt, K. von Bergmann, K.A. Fleming, and R.W. Chapman A preliminary trial of high dose ursodeoxycholic acid in primary sclerosing cholangitis: results of a randomized double-blind placebo-controlled study Gastroenterology 121 2001 900 907
10. D.M. Harnois, P. Angulo, R.A. Jorgensen, N.F. LaRusso, and K.D. Lindor High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis Am J Gastroenterol 96 2001 1558 1562
11. R. Olsson, K.M. Boberg, O.S. de Muckadell, S. Lindgren, R. Hulcrantz, and G. Folvik High-dose ursodeoxycholic acid in primary sclerosing cholangitis. A five year multicenter randomized controlled study. Gastroenterology 129 2005 1464 1472
12. K.D. Lindor, K.V. Knowdley, V.A.C. Luketic, M.E. Harrison, T. McCashland, and A.S. Befeler High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis Hepatology 50 2009 671 673
13. A. Stiehl, G. Rudolph, P. Sauer, C. Benz, W. Stremmel, and S. Walker Efficacy of ursodeoxycholic acid treatment and endoscopic dilatation of major duct stenoses in primary sclerosing cholangitis. An 8 years prospective study J Hepatol 26 1997 560 566
14. A. Stiehl, G. Rudolph, P. Klöters-Plachky, P. Sauer, and S. Walker Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment J Hepatol 36 2002 151 156
15. G. Rudolph, D. Gotthardt, P. Klöters-Plachky, H. Kulaksiz, D. Rost, and A. Stiehl Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis J Hepatol 51 2009 149 155
16. U. Broome, and A. Bergquist Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer Sem Liv Dis 26 2006 31 41
17. A. Ghazale, St. Chari, L. Zhang, C.T. Smyrk, N. Takahashi, and M.J. Levy Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy Gastroenterology 134 2008 706 715 (Pubitemid 351312724)
18. D. Rost, G. Rudolph, P. Kloeters-Plachky, and A. Stiehl Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis Hepatology 40 2004 693 698
19. D. Gotthardt, G. Rudolph, P. Klöters-Plachky, H. Kulaksiz, and A. Stiehl Endoscopic dilatation of dominant stenoses in primary sclerosing cholangitis: outcome after long-term treatment Gastrointest Endosc 71 2010 527 534
20. A. Stiehl Primary sclerosing cholangitis: the role of endoscopic therapy Sem Liv Dis 26 2006 62 68 (Pubitemid 43320728)
21. H. Kulaksiz, G. Rudolph, P. Kloeters-Plachky, P. Sauer, H. Geiss, and A. Stiehl Biliary Candida infections in primary sclerosing cholangitis J Hepatol 45 2006 711 716
22. R.F. Woolson Rank tests and a one-sample log rank test for comparing observed survival data to a standard population Biometrics 37 1981 687 696
23. D.P. Harrington, and T.R. Fleming A class of rank test procedures for censored survival data Biometrika 69 1982 553 566
24. G. Rudolph, P. Kloeters-Plachky, D. Rost, and A. Stiehl The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid Eur J Gastroenterol Hepatol 19 2007 487 491
25. R. Olsson, E. Björnsson, L. Bäckman, S. Friman, K. Höckerstedt, and B. Kaijser Bile duct bacterial isolates in primary sclerosing cholangitis: a study of explanted livers J Hepatol 28 1998 426 432
26. J. Pohl, A. Ring, W. Stremmel, and A. Stiehl The role of dominant stenoses in bacterial infections of bile ducts in primary sclerosing cholangitis Eur J Gastroenterol Hepatol 18 2006 69 74
27. U. Broome, R. Löfberg, B. Veress, and L.S. Erikson Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential Hepatology 22 1995 1404 1408
28. M.M.H. Claessen, F.P. Vleggaar, M.A.J. Tytgat, P.D. Siersema, and H.R. Van Buuren High life-time risk of cancer in primary sclerosing cholangitis J Hepatology 50 2009 158 164
29. B.Y. Tung, M.J. Edmond, R.C. Haggitt, M.P. Bronner, M.B. Kimmey, and K.V. Knowdley Ursodiol use is associated with lower prevalence of colonic neoplasia in cholangitis Ann Intern Med 134 2001 89 95
30. D.S. Pardi, E.V. Loftus, W.K. Kremers, J. Keach, and K.D. Lindor Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis Gastroenterology 124 2003 889 893
31. J. Ludwig, S.S. Barham, R.F. LaRusso, L.R. Elveback, R.H. Wiesner, and J.T. McCall Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis Hepatology 1 1981 632 640
32. M. Rabinovitz, J.S. Gavaler, R.R. Schade, V.J. Dindzans, M.C. Chien, and D.H. Van Thiel Does primary sclerosing cholangitis occurring in association with inflammatory bowel disease differ from that occurring in the absence of inflammatory bowel disease? Hepatology 11 1990 7 11